DOI QR코드

DOI QR Code

Expression and Effects of JMJD2A Histone Demethylase in Endometrial Carcinoma

  • Wang, Hong-Li (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Liu, Mei-Mei (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Ma, Xin (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Fang, Lei (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Zhang, Zong-Feng (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Song, Tie-Fang (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Gao, Jia-Yin (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Kuang, Ye (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Jiang, Jing (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Li, Lin (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Wang, Yang-Yang (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University) ;
  • Li, Pei-Ling (Department of Obstetrics and Gynaecology, Second Affiliated Hospital of Harbin Medical University)
  • 발행 : 2014.04.01

초록

Previous studies have demonstrated that JMJD2A is a potential oncogene and is overexpressed in human tumors. However, its role in the endometrial carcinoma remains largely unknown. In this study, we discovered that JMJD2A was overexpressed in endometrial carcinoma, using immunohistochemistry, quantitative realtime polymerase chain reaction, and western blotting. Downregulation of JMJD2A led to reduced endometrial carcinoma RL95-2 and ISK cell proliferation, invasion and metastasis as asessed with cell counting kit-8, cell migration and invasive assays. Collectively, our results support that JMJD2A is a promoter of endometrial carcinoma cell proliferation and survival, and is a potential novel drug target.

참고문헌

  1. Amant F, Moerman P, Neven P, et al (2005). Endometrial cancer. Lancet, 366, 491-505. https://doi.org/10.1016/S0140-6736(05)67063-8
  2. Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, et al (2004). Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol, 180, 497-504. https://doi.org/10.1677/joe.0.1800497
  3. Arafa M, Somja J, Dehan P, Kridelka F, Goffin F, et al (2010). Current concepts in the pathology and epigenetics of endometrial carcinoma. Pathology, 42, 613-7. https://doi.org/10.3109/00313025.2010.520307
  4. Berger CE, Qian Y, Liu G, Chen H, Chen X (2012). p53, a target of estrogen receptor (ER)${\alpha}$, modulates DNA damage-induced growth suppression in ER-positivebreast cancer cells. J Biol Chem, 287, 30117-27. https://doi.org/10.1074/jbc.M112.367326
  5. Berry WL, Shin S, Lightfoot SA, Janknecht R (2012). Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol, 41, 1701-6. https://doi.org/10.3892/ijo.2012.1618
  6. Berstein LM, Tchernobrovkina AE, Gamajunova VB, et al (2003). Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol, 129, 245-9.
  7. Chao A, Wang TH, Lee YS, et al (2006). Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer, 119, 91-8. https://doi.org/10.1002/ijc.21813
  8. Cloos PA, Christensen J, Agger K, et al (2006). The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature, 442, 307-11. https://doi.org/10.1038/nature04837
  9. Dickson RB, Lippman ME (1995). Growth factors in breast cancer. Endocr Rev, 16, 559-89. https://doi.org/10.1210/edrv-16-5-559
  10. Di Cristofano A, Ellenson LH (2007). Endometrial carcinoma. Ann Rev Pathol, 2, 57-85. https://doi.org/10.1146/annurev.pathol.2.010506.091905
  11. Hecht JL, Mutter GL (2006). Molecular and pathologic aspects ofendometrial carcinogenesis. J Clin Oncol, 24, 4783-91. https://doi.org/10.1200/JCO.2006.06.7173
  12. Li BX, Zhang MC, Luo CL, et al (2011). Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. J Exp Clin Cancer Res, 30, 90. https://doi.org/10.1186/1756-9966-30-90
  13. Katoh M, Katoh M (2004). Identification and characterization of JMJD2 family genes in silico. Int J Oncol, 24, 1623-8.
  14. Kauffman EC, Robinson BD, Downes MJ, et al (2011). Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog, 50, 931-44. https://doi.org/10.1002/mc.20758
  15. Kim TD, Shin S, Berry WL, et al (2012). The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem, 113, 1368-76. https://doi.org/10.1002/jcb.24009
  16. Qin C, Nguyen T, Stewart J, et al (2002). Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of anuclearfactorB/CCAAT- bindingtranscriptionfactor-1complex. Mol Endocrinol, 16, 1793-809. https://doi.org/10.1210/me.2002-0006
  17. Ryan AJ, Susil B, Jobling TW, Oehler MK (2005). Endometrial cancer. Cell and Tissue Research, 322, 53-61. https://doi.org/10.1007/s00441-005-1109-5
  18. Salvesen HB, Haldorsen IS, Trovik J (2012). Markers for individualised therapy in endometrial carcinoma. Lancet Oncol, 13, 353-61. https://doi.org/10.1016/S1470-2045(12)70041-4
  19. Shah YM, Basrur V, Rowan BG (2004). Selective estrogen receptor modulator regulated proteins in endometrial cancer cells. Mol Cell Endocrinol, 219, 127-39. https://doi.org/10.1016/j.mce.2004.01.003
  20. Shin S, Janknecht R (2007). Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun, 359, 742-6. https://doi.org/10.1016/j.bbrc.2007.05.179
  21. Shirley SH, Rundhaug JE, Tian J, et al (2009). Transcriptional regulation of estrogen receptor by p53 in human breast cancer cells. Cancer Res, 69, 3405-14. https://doi.org/10.1158/0008-5472.CAN-08-3628
  22. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  23. Sirbasku DA, Moreno-Cuevas JE (2000). Estrogen mitogenic action. ii. negative regulation of the steroid hormone-responsive growth of cell lines derived from human and rodent target tissue tumors and conceptual implications. In Vitro Cell Dev Biol Anim, 36, 428-46. https://doi.org/10.1290/1071-2690(2000)036<0428:EMAINR>2.0.CO;2
  24. Soto AM, Sonnenschein C (1987). Cell proliferation of estrogen-sensitive cells: the case for negative control. Endocr Rev, 8, 44-52. https://doi.org/10.1210/edrv-8-1-44
  25. Thanapprapasr D, Thanapprapasr K (2013). Molecular therapy as a future strategy in endometrial cancer. Asian Pac J Cancer Prev, 14, 3419-23. https://doi.org/10.7314/APJCP.2013.14.6.3419
  26. Thomas DB (1984). Do hormones cause breast cancer? Cancer, 53, 595-604. https://doi.org/10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y
  27. Tsukada Y, Fang J, Erdjument-Bromage H, et al (2006). Histone demethylation by a family of JmjC domain-containing proteins. Nature, 439, 811-6. https://doi.org/10.1038/nature04433
  28. Vousden KH, and Prives C (2009). Blinded by the light: the growing complexity of p53. Cell, 137, 413-31. https://doi.org/10.1016/j.cell.2009.04.037
  29. Wang XW, Chen YL, Luo YL, Liu QY (2011). No association between the CYP1B1 C4326G polymorphism and endometrial cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 12, 2343-8.

피인용 문헌

  1. Polycystic Ovary Syndrome and Risk of Endometrial Cancer: a Mini-Review vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7011
  2. Critical roles of non-histone protein lysine methylation in human tumorigenesis vol.15, pp.2, 2015, https://doi.org/10.1038/nrc3884
  3. The Polymorphism of Hypoxia-inducible Factor-1a Gene in Endometrial Cancer vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10393
  4. Role of exon 7 PTEN Gene in Endometrial Carcinoma vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4521
  5. SUMO modification of a heterochromatin histone demethylase JMJD2A enables viral gene transactivation and viral replication vol.13, pp.2, 2017, https://doi.org/10.1371/journal.ppat.1006216
  6. Epigenetics in endometrial carcinogenesis – part 2: histone modifications, chromatin remodeling and noncoding RNAs vol.9, pp.6, 2017, https://doi.org/10.2217/epi-2016-0167